Promethera’s mission is to apply its proprietary liver cell-based technology to meet the needs of patients with acute and chronic liver diseases.
Global Innovator in
Liver Cell-based Medicines
Disease Focus
Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).
Pipeline
Promethera’s lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in an open-label Phase 2 clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF), the program is expected to enter clinical development in Non-Alcoholic Steatohepatits (NASH) in the second half of 2017.
International Presence
Promethera Biosciences is headquartered in Mont-Saint-Guibert in the Walloon region of Belgium, which is internationally known for excellence in cell therapy research. Located at the Belgian site are GMP certified manufacturing facilities. The Company’s US subsidiary, Promethera Biosciences LLC, has facilities in Durham, North Carolina. These include commercial operations; GMP certified manufacturing facilities and the organ procurement relations department.
